IL6 and COVID-19: Moreover, IL-6 is considered as a new therapeutic target as it plays a pleiotropic role in activating the inflammatory response [19] and the use of the tocilizumab, a humanized anti-IL-6 receptor antibody, was associated with a lower risk of mortality and mechanical ventilation requirement among COVID-19 patients [20].